Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Growth 2025-2031

Publication ID:

LPI01256671

Publication Date:

January 16, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Human Cytomegalovirus Envelope Glycoprotein B market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Human Cytomegalovirus Envelope Glycoprotein B is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Human Cytomegalovirus Envelope Glycoprotein B players cover Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc, Vical Incorporated, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淗uman Cytomegalovirus Envelope Glycoprotein B Industry Forecast鈥� looks at past sales and reviews total world Human Cytomegalovirus Envelope Glycoprotein B sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Cytomegalovirus Envelope Glycoprotein B sales for 2025 through 2031. With Human Cytomegalovirus Envelope Glycoprotein B sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Cytomegalovirus Envelope Glycoprotein B industry.
This Insight Report provides a comprehensive analysis of the global Human Cytomegalovirus Envelope Glycoprotein B landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Cytomegalovirus Envelope Glycoprotein B portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Human Cytomegalovirus Envelope Glycoprotein B market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Cytomegalovirus Envelope Glycoprotein B and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Cytomegalovirus Envelope Glycoprotein B.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Cytomegalovirus Envelope Glycoprotein B market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Segmentation by Application:
Infectious Disease
Oncology
Women's Health
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
Key Questions Addressed in this Report
What is the 10-year outlook for the global Human Cytomegalovirus Envelope Glycoprotein B market?
What factors are driving Human Cytomegalovirus Envelope Glycoprotein B market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Cytomegalovirus Envelope Glycoprotein B market opportunities vary by end market size?
How does Human Cytomegalovirus Envelope Glycoprotein B break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Human Cytomegalovirus Envelope Glycoprotein B by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Human Cytomegalovirus Envelope Glycoprotein B by Country/Region, 2020, 2024 & 2031
2.2 Human Cytomegalovirus Envelope Glycoprotein B Segment by Type
2.2.1 CSJ-148
2.2.2 CyMVectin
2.2.3 TRL-345
2.2.4 PPCM
2.2.5 Cytomegalovirus Vaccine
2.2.6 Others
2.3 Human Cytomegalovirus Envelope Glycoprotein B Sales by Type
2.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sale Price by Type (2020-2025)
2.4 Human Cytomegalovirus Envelope Glycoprotein B Segment by Application
2.4.1 Infectious Disease
2.4.2 Oncology
2.4.3 Women's Health
2.4.4 Others
2.5 Human Cytomegalovirus Envelope Glycoprotein B Sales by Application
2.5.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Breakdown Data by Company
3.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Annual Sales by Company (2020-2025)
3.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Annual Revenue by Company (2020-2025)
3.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Company (2020-2025)
3.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Sale Price by Company
3.4 Key Manufacturers Human Cytomegalovirus Envelope Glycoprotein B Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Cytomegalovirus Envelope Glycoprotein B Product Location Distribution
3.4.2 Players Human Cytomegalovirus Envelope Glycoprotein B Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Human Cytomegalovirus Envelope Glycoprotein B by Geographic Region
4.1 World Historic Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Annual Sales by Country/Region (2020-2025)
4.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Annual Revenue by Country/Region (2020-2025)
4.3 Americas Human Cytomegalovirus Envelope Glycoprotein B Sales Growth
4.4 APAC Human Cytomegalovirus Envelope Glycoprotein B Sales Growth
4.5 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales Growth
4.6 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales Growth
5 Americas
5.1 Americas Human Cytomegalovirus Envelope Glycoprotein B Sales by Country
5.1.1 Americas Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2025)
5.1.2 Americas Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2025)
5.2 Americas Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2020-2025)
5.3 Americas Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Cytomegalovirus Envelope Glycoprotein B Sales by Region
6.1.1 APAC Human Cytomegalovirus Envelope Glycoprotein B Sales by Region (2020-2025)
6.1.2 APAC Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region (2020-2025)
6.2 APAC Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2020-2025)
6.3 APAC Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Human Cytomegalovirus Envelope Glycoprotein B by Country
7.1.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2025)
7.1.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2025)
7.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2020-2025)
7.3 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B by Country
8.1.1 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2020-2025)
8.1.2 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2020-2025)
8.2 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2020-2025)
8.3 Middle East & Africa Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Cytomegalovirus Envelope Glycoprotein B
10.3 Manufacturing Process Analysis of Human Cytomegalovirus Envelope Glycoprotein B
10.4 Industry Chain Structure of Human Cytomegalovirus Envelope Glycoprotein B
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Cytomegalovirus Envelope Glycoprotein B Distributors
11.3 Human Cytomegalovirus Envelope Glycoprotein B Customer
12 World Forecast Review for Human Cytomegalovirus Envelope Glycoprotein B by Geographic Region
12.1 Global Human Cytomegalovirus Envelope Glycoprotein B 麻豆原创 Size Forecast by Region
12.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Forecast by Region (2026-2031)
12.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Human Cytomegalovirus Envelope Glycoprotein B Forecast by Type (2026-2031)
12.7 Global Human Cytomegalovirus Envelope Glycoprotein B Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Astellas Pharma Inc.
13.1.1 Astellas Pharma Inc. Company Information
13.1.2 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolios and Specifications
13.1.3 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Astellas Pharma Inc. Main Business Overview
13.1.5 Astellas Pharma Inc. Latest Developments
13.2 Trellis Bioscience, Inc.
13.2.1 Trellis Bioscience, Inc. Company Information
13.2.2 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolios and Specifications
13.2.3 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Trellis Bioscience, Inc. Main Business Overview
13.2.5 Trellis Bioscience, Inc. Latest Developments
13.3 Vakzine Projekt Management GmbH
13.3.1 Vakzine Projekt Management GmbH Company Information
13.3.2 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Portfolios and Specifications
13.3.3 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Vakzine Projekt Management GmbH Main Business Overview
13.3.5 Vakzine Projekt Management GmbH Latest Developments
13.4 VBI Vaccine Inc
13.4.1 VBI Vaccine Inc Company Information
13.4.2 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Portfolios and Specifications
13.4.3 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 VBI Vaccine Inc Main Business Overview
13.4.5 VBI Vaccine Inc Latest Developments
13.5 Vical Incorporated
13.5.1 Vical Incorporated Company Information
13.5.2 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Portfolios and Specifications
13.5.3 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Vical Incorporated Main Business Overview
13.5.5 Vical Incorporated Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.